Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
At steady-state, individual patient plasma data showed PAS-004 inhibiting phosphorylated extracellular signal-regulated ...
Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. Pasithea Therapeutics announced positive interim Phase 1 data for PAS-004, showing ...
Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model. Background: Chemokine receptors have been shown to regulate the progression ...
Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...
Jefferies, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback